Active pharmaceutical ingredients UDCA* manufacturing unit is one of Grindeks most significant investment projects. The total contribution of the new manufacturing unit consists of 6.34 million lats, of which 2.8 million lats is the co-financing by the European Regional Development Fund (ERDF).
We invite journalists and media representatives to attend
opening ceremony of UDCA manufacturing unit
Thursday, 16 June at 11.00 a.m.
Grindeks, 53 Krustpils Street, Riga.
In the opening ceremony will take part the Prime Minister of the Republic of Latvia Valdis Dombrovskis, JSC Grindeks Chairman of the Council Kirovs Lipmans, JSC Grindeks Chairman of the Board Janis Romanovskis etc.
After the formal opening ceremony, there will be an excursion to the new manufacturing unit.
Journalists and media representatives are welcome to come to Grindeks by a special bus that will wait at 10.15 a. m. in the parking by the Riga Technical University on Kalku Street in Riga, but, please inform us about it in advance until 12 o’clock noon, 15 June by phones: 67083336 or 26466681.
Further information:
Laila Klavina
Head of the Communications Department
JSC Grindeks
Phones: (+371) 67083370, (+371) 29256012
Fax: (+371) 67083505
E-mail: [email protected]
*Active pharmaceutical ingredient UDCA (ursodeoxycholic acid) is used for production of final dosage forms in the treatment of hepatic and gallstone diseases. It dissolves cholesterol gallstones, and increases hepatocyte membrane stabilizing and resistance functions during harmful exposure, restores damaged hepatocyte membranes, inhibits the abnormal immune response in the liver at cholestatic liver disease.
